Oppenheimer Upgrades Accretive Health (AH) to Outperform; Looking Past 4Q Concerns
Tweet
Share
E-mailGet Alerts AH Hot Sheet
Price: $8.02 --0%
Rating Summary:
2 Buy, 6 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 11 | New: 19
Rating Summary:
2 Buy, 6 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 11 | New: 19
Join SI Premium – FREE
Oppenheimer upgraded Accretive Health (NYSE: AH) from Perform to Outperform with a price target of $31.00.
Oppenheimer analyst said, "While we remain skeptical that AH will achieve management's 4Q11 revenue guidance, we believe the 26% decline in the shares since reporting 3Q11 results removes the risk of a top-line miss. More importantly, we believe the company is well positioned to meet or exceed revenue expectations for 2012. Based on its current PCARR, we estimate AH has 88% of the 2012 consensus revenue estimate covered. We believe incentive fee estimates may also prove to be conservative, assuming the company's QTCoC offering is able to achieve 6% cost trend
reduction. With minimal risk of missing 2012 revenue estimates and the potential for upside, in our opinion, we are upgrading the shares."
For an analyst ratings summary and ratings history on Accretive Health click here. For more ratings news on Accretive Health click here.
Shares of Accretive Health closed at $21.10 yesterday.
Oppenheimer analyst said, "While we remain skeptical that AH will achieve management's 4Q11 revenue guidance, we believe the 26% decline in the shares since reporting 3Q11 results removes the risk of a top-line miss. More importantly, we believe the company is well positioned to meet or exceed revenue expectations for 2012. Based on its current PCARR, we estimate AH has 88% of the 2012 consensus revenue estimate covered. We believe incentive fee estimates may also prove to be conservative, assuming the company's QTCoC offering is able to achieve 6% cost trend
reduction. With minimal risk of missing 2012 revenue estimates and the potential for upside, in our opinion, we are upgrading the shares."
For an analyst ratings summary and ratings history on Accretive Health click here. For more ratings news on Accretive Health click here.
Shares of Accretive Health closed at $21.10 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- BMO Capital Resumes Global Net Lease (GNL), Upgrades to Outperform
- Investec Double Upgrades Alkem Laboratories Ltd (ALKEM:IN) to Buy
Create E-mail Alert Related Categories
UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
